IMRIS Inc. Company Profile

16:11 EDT 23rd September 2017 | BioPortfolio

News Articles [3 Associated News Articles listed on BioPortfolio]

IMRIS CEO Jay D. Miller to present at Canaccord Genuity 33rd Annual Global Growth Conference

WINNIPEG and MINNEAPOLIS, Aug. 9, 2013 /PRNewswire/ - IMRIS Inc. (NASDAQ: IMRS; TSX: IM) will present at the Canaccord Genuity 33rd Annual Global Growth Conference in Boston at 10 am Eastern Time on...

IMRIS' Annual Sales Grow Nearly 50% After Bankruptcy Sale

  Life Sciences Jobs   ...

IMRIS Reports Strong Financial Growth Following Two-Year Anniversary Under New Ownership

MINNETONKA, Minn., Sept. 12, 2017 /PRNewswire/ -- IMRIS, the global leader in intraoperative imaging, recently celebrated its two-year anniversary under new ownership with strong financial growth and ...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

A Study of IMRT in Primary Bone and Soft Tissue Sarcoma

IMRiS is a phase II trial which aims to assess the feasibility, efficacy and toxicity of Intensity Modulated Radiotherapy (IMRT) in three different cohorts of patients with primary bone an...

More Information about "IMRIS Inc." on BioPortfolio

We have published hundreds of IMRIS Inc. news stories on BioPortfolio along with dozens of IMRIS Inc. Clinical Trials and PubMed Articles about IMRIS Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of IMRIS Inc. Companies in our database. You can also find out about relevant IMRIS Inc. Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks

Searches Linking to this Company Record